Valencia healthtech Quibim closes $50m Series A

Valencia-based Quibim, a healthtech company pioneering the use of imaging biomarkers for precision medicine, announced the close of its $50 million Series A financing.

Quibim said it has experienced “remarkable” growth in the number of patients analyzed by its products over the past year.

“Driven by several regulatory approvals and global commercial partnerships, patient analysis surged by 168% quarter-on-quarter,” said Quibim.

The financing was led by Asabys through its fund Sabadell Asabys II and Buenavista Equity Partners through the BHG I fund, created in partnership with Columbus Venture Partners.

They were joined by UI Investissements, and GoHub Ventures as new investors.

They were also joined by current investors, Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund’s early growth fund), Tony Fadell’s Build Collective, and individual investor Dr. Jonathan Milner, founder of Abcam plc.

Quibim said it is dedicated to the ambitious mission of unlocking a complete, non-invasive understanding of every tissue point in the human body, at any moment in time. To achieve this, the company develops foundational AI models applied to imaging that extract actionable insights from MRI, CT, and PET scans.

“These insights enable precise characterization of phenotypes and prediction of outcomes in areas such as oncology, immunology, neurology and metabolic disorders,” said the firm.

“This is the pathway toward achieving human digital twins, dynamic models that not only reflect and allow health monitoring but also enhance patient stratification, improve the success rates of drug development programs, and enable treatment testing before application. Today, the company is building digital twins at the organ and lesion level, exemplified by solutions like QP-Brain, QP-Prostate, and QP-Liver.

“However, as the volume of whole-body scans and related imaging data continues to grow, in the coming years Quibim models will analyze the entire body. The vision of the company is to catalyze this revolutionary step in healthcare by merging imaging technologies, computing, and AI.

“With over 170 installations worldwide, including prestigious institutions like Mass General Brigham and Stanford, and regulatory clearances across the US, EU, UK, and other regions, Quibim’s technology bridges the gap between research, clinical practice, and drug development.

“Last year, Philips announced a global partnership with Quibim to integrate its AI models into MR scanners, while the company also secured strategic alliances with leading biopharma giants such as Merck KGaA and Novartis.”

Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim, said: “Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support.

“Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionize diagnostics and improve patient outcomes.”

With the series A financing, Quibim is establishing a US presence.

“Asabys is thrilled to support Quibim in transforming the imaging diagnostics space,” said Guillem Masferrer, Partner at Asabys Partners. “Their ability to combine AI with imaging biomarker discovery addresses critical unmet needs in oncology, neurology, and beyond. We are confident that Quibim’s innovative solutions will have a profound impact on global healthcare.”

José Mesa, Partner at Columbus and Buenavista’s representative on the Quibim board, said: “Quibim’s technology exemplifies the next wave of precision medicine.

“Their impressive track record with global pharmaceutical partnerships, including partnerships with companies such as Merck KGaA and Philips, exemplify Quibim’s role in transforming imaging data into valuable predictions for clinical trials and treatment planning. We expect that as Quibim develops its pipeline of companion diagnostic tools, we will see tremendous momentum for its technology and products.”